Poractant Alpha
- Atc Codes:R07AA
- CAS Codes:129069-19-8
- PHARMGKB ID:129069-19-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Curosurf; Belgium: Curosurf, Survanta; Denmark: Curosurf; Finland: Curosurf; France: Curosurf; Germany: Curosurf; Hungary: Curosurf, Survanta; Ireland: Curosurf; Italy: Curosurf; Latvia: Curosurf; Lithuania: Curosurf; Luxembourg: Curosurf; Netherlands: Curosurf; Poland: Curosurf; Portugal: Curosurf; Spain: Curosurf; Sweden: Curosurf; UK: Curosurf.
North America
USA: Curosurf.
Latin America
Argentina: Surfactante, Survanta-Abbot; Brazil: Curosurf.
Drug combinations
Chemistry
Poractant Alpha: extract of porcine lung containing 99% lipids, mainly phospholipids, and about 1% of hydrophobic proteins (SP-B and SP-C). CAS-129069-19-8.
Pharmacologic Category
Pulmonary Surfactants. (ATC-Code: R07AA).
Mechanism of action
Reduces surface tension at air-liquid interface of alveoli during ventilation and stabilizes alveoli against collapse at resting transpulmonary pressures.
Therapeutic use
Treatment of respiratory distress syndrome in premature infants.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Warnings and precautions
Pulmonary hemorrhage reported in infants who received poractant. Transient adverse effects (bradycardia, decreased oxygen saturation, hypotension, or endotracheal tube blockage) may occur. For intratracheal administration only. Hypotension, anemia, hypoglycemia, and hypothermia should be corrected before use. Produces rapid improvements in lung oxygenation and compliance.